SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced financial results for the fourth quarter and year ended December 31, 2006. In addition, the Company is providing a summary of feedback from a recent face-to-face meeting with the Department of Health and Human Services (HHS) regarding NEUMUNE® (HE2100) for the treatment of acute radiation syndrome (ARS), as well as a review of the status of NEUMUNE and its other development programs.
